Novartis 1Q Revenues: $11.9 billion (-7%) 1Q Earnings: $2.3 billion (-6%) Comments: Pharmaceutical sales were $7.1 billion in the quarter, down 9%, and included the new oncology assets acquired from GSK (sales of $0.2 billion in March), offset by the negative impact of generic competition, largely for Diovan, Exforge and Vivelle-Dot in the U.S. Growth Products, which include Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, the COPD portfolio, and Jakavi – generated $2.9 billion, up...